UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
------------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
------------------------
Date of Report (Date of earliest event reported): March 5, 2000
IMMUNOGEN, INC.
(Exact name of registrant as specified in its Charter)
Massachusetts 0-17999 04-2726691
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
128 Sidney Street, Cambridge, Massachusetts 02139
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (617) 995-2500
ITEM 5. OTHER EVENTS
On March 5, 2001, ImmunoGen, Inc. ("ImmunoGen") announced the appointment of
Gregg D. Beloff as Vice President and Chief Financial Officer.
The press release announcing the appointment of Mr. Beloff is incorporated
herein by reference and filed as Exhibit 99.1 hereto.
On March 5, 2001, ImmunoGen announced that it entered into a collaboration
agreement with Millennium Pharmaceuticals, Inc.
The press release announcing the collaboration agreement with Millenium is
incorporated herein by reference and filed as Exhibit 99.2 hereto.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS
(c) Exhibits.
99.1 The Registrant's Press Release dated March 5, 2001.
99.2 The Registrant's Press Release dated March 5, 2001.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereto duly authorized.
ImmunoGen, Inc.
(Registrant)
Date: March 7, 2001 /s/ MITCHEL S. SAYARE
--------------------------------
Mitchel S. Sayare
Chairman and CEO